Literature DB >> 135639

Cytogenetic studies and clinical implications in patients with Sézary syndrome.

J Whang-Peng, M Lutzner, R Edelson, T Knutsen.   

Abstract

Chromosome studies were carried out on 11 National Institutes of Health (N.I.H.) patients who had the diagnosis of Sézary syndrome. Heteroploidy, multiple markers including minute and ring chromosomes, and a lack of modality and clone formation, were the common chromosomal findings in this syndrome. Abundant spontaneous division of heteroploid cells in unstimulated peripheral blood cultures, a high percentage of heteroploid cells in stimulated culture, and finally, clone formation, are signs of a fulminant process and lead to the terminal phase of this disease. Early chemotherapeutic eradication of these heteroploid neoplastic cells would, therefore, be the treatment of choice in this disease.

Entities:  

Mesh:

Year:  1976        PMID: 135639     DOI: 10.1002/1097-0142(197608)38:2<861::aid-cncr2820380233>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Outsmarting cutaneous T-cell lymphoma cells by decoding the language they speak: focusing past and present insights on future prospects.

Authors:  Richard L Edelson
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-09

2.  Dual parameter flow cytometry studies in human lymphomas.

Authors:  S E Shackney; K S Skramstad; R E Cunningham; D J Dugas; T L Lincoln; R J Lukes
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

Review 3.  Genotraumatic T cells and cutaneous T-cell lymphoma. A causal relationship?

Authors:  K Thestrup-Pedersen; K Kaltoft
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

4.  A Munc18-1 mutant mimicking phosphorylation by Down Syndrome-related kinase Dyrk1a supports normal synaptic transmission and promotes recovery after intense activity.

Authors:  Jessica Classen; Ingrid Saarloos; Marieke Meijer; Patrick F Sullivan; Matthijs Verhage
Journal:  Sci Rep       Date:  2020-02-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.